Table 1.
Characteristics of men and tumors with MSK-IMPACT sequencing.1
| By self-reported race | ||||
|---|---|---|---|---|
| Overall | White | Asian | Black | |
| 2,069 | 1,841 | 63 | 165 | |
| Age at diagnosis (years) | 63 (56, 68) | 63 (56, 68) | 63 (57, 68) | 60 (53, 64) |
| Age at sample (years) | 66 (59, 72) | 66 (59, 72) | 66 (60, 70) | 62 (56, 69) |
| Diagnosis to sample (months) | 3 (0, 43) | 3 (0, 42) | 4 (0, 29) | 3 (0, 50) |
| Diagnosis to sequencing (months) | 26 (6, 83) | 27 (6, 83) | 18 (7, 60) | 24 (6, 84) |
| Smoking status | ||||
| Never | 1,099 (55%) | 981 (55%) | 38 (60%) | 80 (49%) |
| Former | 783 (39%) | 698 (39%) | 24 (38%) | 61 (38%) |
| Current | 132 (7%) | 110 (6%) | 1 (2%) | 21 (13%) |
| Unknown | 55 | 52 | 0 | 3 |
| Area-level household income ($/year) | 115,844 (84,643, 156,558) | 119,884 (90,293, 158,420) | 119,780 (89,288, 160,935) | 72,568 (54,886, 96,086) |
| Unknown | 40 | 39 | 0 | 1 |
| PSA at diagnosis (ng/ml) | 9.2 (5.3, 26.8) | 8.8 (5.2, 23.3) | 17.9 (6.8, 97.0) | 17.0 (7.0, 94.5) |
| Unknown | 116 | 104 | 2 | 10 |
| Gleason grade | ||||
| <7 | 171 (9%) | 159 (9%) | 3 (5%) | 9 (6%) |
| 3+4 | 287 (15%) | 249 (15%) | 9 (16%) | 29 (19%) |
| 4+3 | 336 (18%) | 294 (17%) | 12 (21%) | 30 (19%) |
| 8 | 381 (20%) | 338 (20%) | 11 (19%) | 32 (21%) |
| 9–10 | 726 (38%) | 648 (38%) | 23 (40%) | 55 (35%) |
| Unknown | 168 | 153 | 5 | 10 |
| Stage (M) | ||||
| M0 | 1,501 (73%) | 1,341 (73%) | 39 (62%) | 121 (73%) |
| M1 | 568 (27%) | 500 (27%) | 24 (38%) | 44 (27%) |
| Sample tissue | ||||
| Prostate | 1,352 (65%) | 1,217 (66%) | 34 (54%) | 101 (61%) |
| Lymph node | 331 (16%) | 284 (15%) | 15 (24%) | 32 (19%) |
| Bone | 191 (9%) | 166 (9%) | 8 (13%) | 17 (10%) |
| Visceral | 125 (6%) | 110 (6%) | 3 (5%) | 12 (7%) |
| Other soft tissue | 70 (3%) | 64 (3%) | 3 (5%) | 3 (2%) |
| Extent of disease at sample | ||||
| Localized | 700 (34%) | 630 (34%) | 16 (25%) | 54 (33%) |
| Regional nodes | 362 (17%) | 324 (18%) | 9 (14%) | 29 (18%) |
| Metastatic hormone-sensitive | 578 (28%) | 512 (28%) | 18 (29%) | 48 (29%) |
| Non-metastatic castration-resistant | 17 (1%) | 16 (1%) | 0 (0%) | 1 (1%) |
| Metastatic castration-resistant | 405 (20%) | 353 (19%) | 20 (32%) | 32 (19%) |
| Metastatic, variant histology | 7 (0%) | 6 (0%) | 0 (0%) | 1 (1%) |
| Tumor cellularity by pathologist (%) | 40 (20, 50) | 40 (20, 50) | 40 (20, 50) | 40 (20, 50) |
| Unknown | 11 | 9 | 1 | 1 |
| Mean sequencing coverage (X) | 611 (461, 754) | 612 (461, 753) | 648 (539, 793) | 581 (453, 737) |
| Consent for germline analyses | 1,781 (86%) | 1,583 (86%) | 54 (86%) | 144 (87%) |
1
Values are count (percent) or median (quartile 1, quartile 3)